Veteran Genomics and Biotech Executive Dean Schorno, CPA, Joins 23andMe as Chief Financial Officer and Head of Operations

August 17, 2015

Following this year’s landmark FDA clearance for genetic health reports, company will use funds to fuel customer growth and further invest in its research platform

Mountain View, Calif. – August 17, 2015 – 23andMe, Inc. today announced the appointment of Dean Schorno, CPA, as chief financial officer and head of operations for the company. In his new role, Schorno will oversee 23andMe’s global financial and clinical laboratory operations. Schorno brings a wealth of experience to the job, most recently, serving as chief financial officer of Adaptive Biotechnologies. Before that he held executive leadership positions at Genomic Health.

“In the last 18 months we’ve made significant investments into the future of our company. This includes starting a therapeutics group led by Dr. Richard Scheller, expanding our product offering internationally, and pursuing a regulatory path to bring our health product back to our US customers,” said Andy Page, president of 23andMe. “Dean Schorno is a world class financial executive with deep operational and category experience who will bring discipline to the complexities of our business.”

As CFO at Adaptive Biotechnologies, Schorno led all financial operations which included a significant financing and acquisition for the company. He was also responsible for laboratory operations and facilities management. Prior to his role at Adaptive Biotechnologies, Schorno spent 13 years at Genomic Health, where he served as both vice president of operations and chief financial officer. During his tenure he oversaw the launch and operations of Genomic Health’s clinical laboratory, as well as the company’s global financial affairs. Prior to Genomic Health, Schorno founded a successful CPA and consulting firm that he led for nearly a decade.

“I look forward to applying my years of industry experience at 23andMe,” said Dean Schorno, chief financial officer and head of operations, 23andMe. “23andMe is the model for direct-to-consumer genetics and has pioneered a new way of engaging consumers in research. I am excited to be able to be a part of a mission driven organization that has changed the way consumers access, understand and benefit from genetic information.”

Schorno holds a Bachelor of Science degree in Business Administration from the University of California, Berkeley, and a Master of Science in Taxation from Golden Gate University. He is a Certified Public Accountant.

About 23andMe

23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.